SC 13G: Xilio Therapeutics, Inc.
Ticker: XLO · Form: SC 13G · Filed: Sep 27, 2024 · CIK: 1840233
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Xilio Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 1,188 words · 5 min read · ~4 pages · Grade level 10 · Accepted 2024-09-27 21:36:39
Key Financial Figures
- $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie
Filing Documents
- gkcc_sch13g.htm (SC 13G) — 52KB
- 0001068238-24-000192.txt ( ) — 53KB
(a). Name of Issuer
Item 1(a). Name of Issuer: Xilio Therapeutics, Inc.
(b). Address of Issuer's Principal Executive Offices
Item 1(b). Address of Issuer's Principal Executive Offices: 828 Winter Street, Suite 300 Waltham, MA 02451
(a). Name of Person Filing
Item 2(a). Name of Person Filing 1. GKCC, LLC 2. Yekaterina Chudnovsky
(b). Address of Principal Business Office or, if none, Residence
Item 2(b). Address of Principal Business Office or, if none, Residence: The address of the Reporting Persons is 501 Silverside Road, Suite 87AVA, Wilmington, DE 19809.
(c). Citizenship
Item 2(c). Citizenship: See Row 4 of cover page for each Reporting Person.
(d). Title of Class of Securities
Item 2(d). Title of Class of Securities. Common Stock, par value $0.0001 per share ("Common Stock")
(e). CUSIP Number
Item 2(e). CUSIP Number: 98422T100 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.
Ownership
Item 4. Ownership. (a) Amount beneficially owned: See Row 9 of cover page for each Reporting Person. (b) Percent of class: See Row 11 of cover page for each Reporting Person. (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person. (ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person. (iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person. (iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Ownership of 5 Percent or Less of a Class
Item 5. Ownership of 5 Percent or Less of a Class. Not applicable.
Ownership of More than 5 Percent on Behalf of Another Person
Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Not applicable.
Identification and Classification of Members of the Group
Item 8. Identification and Classification of Members of the Group. Not applicable.
Notice of Dissolution of Group
Item 9. Notice of Dissolution of Group. Not applicable.
Certifications
Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 27, 2024 GKCC, LLC By: /s/ Yekaterina Chudnovsky Name: Yekaterina Chudnovsky Title: Manager YEKATERINA CHUDNOVSKY /s/ Yekaterina Chudnovsky EXHIBITS A: Joint Filing Agreement Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Xilio Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts. In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 27th day of September, 2024. GKCC, LLC By: /s/ Yekaterina Chudnovsky Name: Yekaterina Chudnovsky Title: Manager YEKATERINA CHUDNOVSKY /s/ Yekaterina Chudnovsky